TGFB1 and pulmonary fibrosis: Lisinopril, a potent inhibitor of angiotensin converting enzyme, has shown promise in reducing hydroxyproline and collagen levels in pulmonary fibrosis models by inhibiting angiotensin II and TGF-β1 [60].